Evidence map›Paper›PMID 35831099›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2022

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.

Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kantaro IshitsukaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Yasuhisa YokoyamaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Naoko BabaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Ryota MatsuokaDepartment of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Noriaki SakamotoDepartment of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Tatsuhiro SakamotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Manabu KusakabeDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Takayasu KatoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Naoki KuritaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Hidekazu NishikiiDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Naoshi ObaraDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Yuichi HasegawaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Shigeru ChibaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
University of Tsukuba · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder which leads to liver failure as a result of progressive destruction of the intrahepatic bile ducts. There are no treatment modalities for VBDS itself and severe hepatic dysfunction restricts the treatment of underlying diseases. We safely treated a case of classic Hodgkin lymphoma (HL) with VBDS using brentuximab vedotin (BV). The patient was treated with 5 cycles of reduced BV and a partial metabolic response was obtained. Moreover, a standard dose of BV for another 5 cycles was accomplished with minimal adverse events. Our experience indicates that BV could be a treatment option for classic HL with VBDS.

Indexed as

Hodgkin DiseaseLiver FailureBile Ducts, IntrahepaticBrentuximab VedotinHumansBrentuximab Vedotinbrentuximab vedotinHodgkin lymphomaliver failurevanishing bile duct syndrome

Identifiers

PMID35831099
PMCPMC9635035
OpenAlexW4285022638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.